TapImmune Inc. (NASDAQ:MRKR) stock end the session high on Friday.
MRKR stock gained over 9.90% to close at $2.77. More than 4.79 million shares traded hands for the session, compared to its 30-day average volume of 3.97 million shares. The stock opened at $2.57 and moved within a range of $2.5100 – 2.8780 on Friday.
MRKR Business Description
Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets.
The company’s MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
|SHARES OUTSTANDING||83.01 M|
|SHARE FLOAT (%)||56.64 M (68.23%)|
|% HELD BY INSTITUTIONS||22.00|
Recent Stock Performance
|+/- EMA(20)||2.39 (+15.90%)|
|+/- SMA(50)||2.27 (+22.03%)|
|+/- SMA(200)||1.94 (+42.78%)|
|CCI20||165.2211||Buy||Chaikin Money Flow||0.0672||Buy|
|MACD||0.0440||Buy||Money Flow Index||55.1320||Buy|
|STOCH (14,3)||86.9048||OverBought||STOCH RSI||1.0000||OverBought|